If you have fibromyalgia, you’ve probably been through the full gauntlet: sleep medications, antidepressants, anticonvulsants, physical therapy — and still wake up hurting. I’ve had this conversation hundreds of times in my clinic over the past two decades. That’s why I want to talk about a treatment that doesn’t get nearly enough attention: low dose naltrexone, or LDN.
This isn’t a fringe therapy. The evidence is growing, the mechanism is well-understood, the side effect profile is remarkably mild, and the cost is low. Here’s what I tell my patients.
What Is Low Dose Naltrexone?
Naltrexone is an FDA-approved opioid antagonist — a medication that blocks opioid receptors. At its standard dose of 50 mg per day, it’s used to treat opioid use disorder and alcohol dependence. At one-tenth of that dose — typically 1.5 to 4.5 mg per day — it behaves in a completely different way, acting on pathways that have nothing to do with blocking opioids.
That distinction is important. LDN is not an opioid. It doesn’t cause dependence, it doesn’t impair cognition, and it doesn’t appear on drug screens as a controlled substance. It’s a fundamentally different drug at a fundamentally different dose.
Because LDN isn’t manufactured at low doses commercially, it requires a compounding pharmacy to prepare — usually as a capsule or liquid.
Why LDN Works for Fibromyalgia: The Mechanism
Fibromyalgia is increasingly understood as a disorder of central sensitization — the central nervous system amplifies pain signals, turning down the volume dial on pain tolerance across the whole body. The microglial cells in your brain and spinal cord, which normally function as the immune system’s first responders in the CNS, become chronically activated. Once activated, they release pro-inflammatory cytokines — including TNF-alpha, IL-1β, and nitric oxide — that drive ongoing pain hypersensitivity.
This is where LDN does something elegant.
Naltrexone, at low doses, acts as an antagonist at Toll-like receptor 4 (TLR4) — a non-opioid receptor found on microglia and macrophages. By blocking TLR4, LDN interrupts the cycle of microglial activation, reduces cytokine release, and dials down the neuroinflammation that underlies central sensitization. This effect is entirely independent of its opioid receptor activity.
LDN also produces a brief, transient blockade of opioid receptors — just long enough to trigger a rebound effect. The body responds by upregulating its own endorphin and enkephalin production, essentially recalibrating the pain modulation system.
In simple terms: LDN quiets the brain’s overactive pain amplifier and nudges your body to produce more of its own natural pain relievers.
What the Research Shows
The evidence for LDN in fibromyalgia has strengthened considerably in recent years.
A 2024 systematic review and meta-analysis published in the Korean Journal of Pain found that LDN significantly reduced pain scores compared to placebo — with a pooled standardized mean difference of –0.851 — and improved function and quality of life, with a favorable safety profile across all included trials.
A separate 2025 meta-analysis published in Annals of Medicine and Surgery reached similar conclusions. Findings were also presented at ACR Convergence 2025, where researchers reported that LDN “significantly reduces pain and improves functional outcomes” in fibromyalgia patients.
An earlier landmark pilot study out of Stanford University (Younger et al.) used 4.5 mg nightly and found a 30% reduction in pain compared to placebo, with participants also reporting improvements in fatigue, sleep quality, and overall quality of life. A 2017 follow-up study measuring pro-inflammatory cytokine levels found significant reductions after 8 weeks of LDN — direct mechanistic confirmation of its anti-inflammatory effect.
I want to be honest: the overall evidence base is still maturing. The trials are relatively small, and not every study has shown benefit — a Lancet Rheumatology trial using 6 mg in women with fibromyalgia did not show superiority over placebo in its primary pain endpoint. Larger phase III trials are needed. But the signal is consistent, the mechanism is credible, and when I weigh that against the safety profile and what I observe clinically, I find LDN a compelling option for appropriately selected patients.
Who Is a Good Candidate for LDN?
In my practice at University Pain Consultants, I consider LDN for fibromyalgia patients who:
- Have not achieved adequate relief with standard first-line treatments (duloxetine, milnacipran, pregabalin, gabapentin)
- Are not currently taking opioid medications — LDN and opioids cannot be used together, as the naltrexone will block the opioid’s effect and may precipitate withdrawal
- Have no significant liver disease (we check liver enzymes before starting)
- Are not dependent on opioids or using them for pain management
- Have a reasonably stable mental health picture
LDN may also be worth considering when fibromyalgia co-exists with inflammatory bowel disease, multiple sclerosis, or chronic fatigue syndrome/ME-CFS — all conditions sharing a neuroinflammatory component where LDN has emerging evidence.
What to Expect: Dosing and Timeline
LDN requires a prescription and compounding. Most compounding pharmacies prepare it as a capsule or liquid at a cost of $30–$60 per month — far less than most specialty medications.
My typical starting protocol:
- Week 1–2: 1.5 mg nightly (taken at bedtime, or 2–4 hours before if sleep is disrupted)
- Week 3–4: Increase to 3.0 mg if well tolerated
- Maintenance: 4.5 mg nightly, continued long-term if effective
Most patients don’t feel a dramatic effect in week one. LDN typically requires 4 to 12 weeks to show meaningful benefit. I always address this upfront — people who don’t know this often give up too soon.
Side Effects: What to Expect and How to Manage Them
LDN has a genuinely favorable side effect profile — one of the main reasons I find it compelling for fibromyalgia patients who are often already burdened by medication side effects.
The most common side effect is vivid or unusual dreams, experienced by up to 30% of patients in the first few weeks. These are generally not nightmares — just more intense, colorful, emotionally memorable dreams. For most people they resolve within one to two weeks. If they persist, taking LDN 2–4 hours before sleep (rather than at bedtime) resolves the issue for the majority of patients.
Other reported side effects include mild insomnia during the first one to two weeks, occasional mild nausea, and headache — all uncommon and typically brief. Serious adverse events have not been a significant finding in LDN trials. It does not cause dependence, weight gain, or cognitive impairment.
The one firm contraindication: LDN cannot be combined with opioid medications. If you are taking any opioid — including tramadol — LDN is not the right choice unless you can transition off opioids first.
How LDN Fits Into a Comprehensive Fibromyalgia Treatment Plan
I don’t position LDN as a standalone cure. Fibromyalgia responds best to a multimodal approach. In my practice, LDN typically works alongside aerobic exercise (still the single most evidence-supported intervention for fibromyalgia), sleep optimization, stress reduction, and other medications as needed. In patients with a significant musculoskeletal component contributing to their overall pain burden, PRP therapy can also be part of the conversation.
LDN is a tool that can meaningfully reduce the baseline of central sensitization — which then makes every other intervention more effective.
A Note on Off-Label Use
LDN for fibromyalgia is an off-label use of naltrexone. The FDA has not specifically approved it for this indication, but off-label prescribing is common, legal, and well-established in medicine — many routine fibromyalgia treatments (gabapentin, tricyclic antidepressants) are also off-label. Off-label simply means the drug hasn’t gone through the specific approval process for that indication. I always have a thorough conversation with patients about this before prescribing.
Considering LDN for Fibromyalgia?
If you’re in the Inland Empire area and want to discuss whether LDN is appropriate for your situation, I’m happy to do a thorough evaluation. At University Pain Consultants, we cover the full spectrum of interventional and regenerative pain care — we figure out what’s actually driving your pain and build a plan around that.
Call us at 951-900-3253 or visit upcregenmed.com to schedule a consultation.
Rainier Guiang, MD is board-certified in Anesthesiology and Pain Medicine (ABA) and has practiced interventional and regenerative pain medicine in the Inland Empire since 2005. He is the director of University Pain Consultants’ Regenerative Medicine program, specializing in PRP therapy, IV ketamine infusions, and low dose naltrexone for chronic pain conditions.
